Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Pfizer's COVID-19 Oral Therapy To Be Tested In Hospitalized COVID-19 Patients In UK: Reuters

Pfizer Inc's (NYSE: PFE) oral COVID-19 therapy will be evaluated as a potential treatment for hospitalized COVID-19 patients in a major British trial.

Benzinga

Check Out What Whales Are Doing With PFE

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 17 strange trades.

Benzinga

Teen COVID boosters being considered

Case numbers of COVID-19 have been increasing across the country in recent days due to infections linked to an Omicron sub-variant.

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins

Key takeaways:

Benzinga

Antiviral drug to be trialled in hospitalised Covid patients

Having already been approved for early-stage treatment of Covid, scientists will now assess how Paxlovid performs when administered to people hospitalised with infection

The Independent UK

Why the UK can’t rely on boosters to get through each new wave of Covid

The evidence suggests performance could be less predictable and effective in the future – though there are promising developments, says Danny Altmann, a professor of immunology at Imperial College London

The Guardian - UK

2nd COVID Vaccine Booster Significantly Lowers Death Rate, Israeli Study Shows

Senior citizens who received a second booster of the Pfizer–BioNTech COVID-19 vaccination had a 78% lower mortality rate from the disease than those who got one only, a study from Israel showed on Sunday. The country's largest healthcare provider, Clalit Health Services, said the 40-day study included more than half…

Asharq Al-Awsat

Read news from The Economist, FT, and more,
with one subscription

COVID-19 boosters, BA.2 subvariant, treatments: 6 things we still need to keep an eye on

Coronavirus case numbers have plummeted across much of the U.S., including Texas, a promising sign that COVID-19 could finally be waning. But the pandemic is far from over, especially for older adults, people with disabilities and other vulnerable populations.

Tribune News Service

KTR showcases Telangana to pharma majors

Meets top leadership of Pfizer, Johnson & Johnson and GSK as part of his official tour to the US

The Hindu

Covid vaccinations in US fall to lowest level since 2020

Public health experts say the low number of Americans receiving booster shots is an ‘unforgivable liability’

The Independent UK

3 Vaccine Stocks to Buy Following the Surge in COVID-19 Cases in China

China is battling with its worst COVID-19 outbreak since 2020. Surging cases of a new omicron variant worldwide are raising concerns that another COVID-19 wave is coming, which could drive demand for future vaccine orders. This bodes well for popular vaccine stocks Pfizer (PFE), Moderna (MRNA), and BioNTech (BNTX), and…

StockNews.com

FDA advisory panel to discuss Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK

FDA advisory panel to discuss additional Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK

Pfizer's RSV Vaccine Candidate Receives FDA Breakthrough Therapy Tag For Prevention of RSV In Older Adults

The FDA has granted Breakthrough Therapy Designation to Pfizer Inc's (NYSE:PFE) respiratory syncytial virus (RSV) vaccine candidate (PF-06928316 or RSVpreF) to prevent lower respiratory tract disease caused by RSV in 60 years of age or older. The positive results primarily inform the FDA decision of Phase 2a study evaluating the safety, immunogenicity, and efficacy…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Caixin Global

Fosun Reports $157 Million of China mRNA Vaccine Sales in 2021

BioNTech partner markets the advanced-tech inoculation in Hong Kong, Macao and Taiwan as regulators haven’t cleared the shots for the mainland

The Independent UK

EXPLAINER: What to know about COVID vaccines for little kids

Moderna says it will ask regulators to authorize its COVID-19 vaccine for children under 6 but several hurdles need to be cleared before the shots could become available

Benzinga

Pfizer's Ulcerative Colitis Candidate Aces Late-Stage Study

Pfizer Inc (NYSE:PFE) has announced topline results from a Phase 3 study of etrasimod in moderately to severely active ulcerative colitis (UC). In the study, etrasimod patients achieved statistically significant improvements in the primary endpoint of clinical remission at week 12 compared with placebo. Statistically significant improvements were achieved in all key secondary…

Tribune News Service

Moderna to seek emergency authorization for COVID-19 vaccine use for kids under 6

Kids, prep those arms.

Get all your
news in one place.

100’s of premium titles.
One news app.

Daily Mirror

When will the Covid spring booster jab be available for young people?

Rollout has begun across the UK for the Covid spring booster. Here's who is eligible for the second booster dose and when young people will be able to get their fourth coronavirus vaccine

Salon

Pfizer CEO pushes yearly Covid shots

Assertions by pharmaceutical company executives have created pressure for scientists and politicians to take action

The Independent UK

Moderna says its low-dose COVID shots work for kids under 6

Moderna says its COVID-19 vaccine works in babies, toddlers and preschoolers

Benzinga

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale

Here's a roundup of top developments in the biotech space over the last 24 hours.

The Independent UK

FDA advisory panel to discuss additional Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

Salon

Docs unconvinced we need two boosters

Vaccine-makers are seeking approval for a second booster. Some doctors don’t think the evidence is strong

Benzinga

Moderna Bolsters Its Pipeline With Two New mRNA-Based Vaccine Programs

Moderna Inc (NASDAQ:MRNA) expands its mRNA pipeline with two new development programs ahead of Annual Vaccines Day, building on Moderna's experience with Spikevax, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four endemic human coronaviruses (HCoV). First, Moderna is launching a respiratory combination…

1 … 59 60 61 62

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Imperial College London

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.